Synchron

University of Melbourne researchers studied one participant implanted with a Stentrode endovascular brain-computer interface who attempted to handwrite English characters. They classified the attempts offline and online using neural signal trajectories over time. Across four online sessions, each containing 20-30 trials per character and 80-180 rest trials, the best-performing 3-class model achieved a mean rest recall of 87%, character recall of 65%, and character precision of 59%. Adjusting all trials to the same duration significantly improved classification compared with raw trials. The findings support further investigation of temporal information for motor decoding, but come from one participant and a small number of classes.

Researchers evaluated the technical feasibility of a multimodal imaging workflow for deploying Synchron's Stentrode endovascular brain-computer interface in a human head phantom. The workflow — thin-slice CT, transfer of DICOM data to an external core laboratory for target identification and marking, re-import of the marked CT, 3D rotational angiography, and registration with the marked reconstruction and intraoperative fluoroscopy — produced a dataset suitable for anatomical analysis, with the core laboratory marking the intended deployment region and the markings persisting through transfer and re-import, and the annotated CT fusing with 3D angiography without significant misregistration or artifacts. The authors say the workflow can generate intraprocedural targeting guidance for Stentrode deployment, as a preclinical technical validation.

Synchron raised a $200 million Series D led by Double Point Ventures, taking its total funding to $345 million. The company plans to use the capital to commercialize its Stentrode endovascular BCI, prepare pivotal trials and expand its AI and engineering teams. Synchron said 10 people with paralysis had received the implant in U.S. and Australian trials at the time of the announcement.

Synchron reported 12-month results from the U.S. COMMAND early feasibility study in six people with severe chronic bilateral upper-limb paralysis. All participants met the primary safety endpoint of no device-related serious adverse event causing death or permanent increased disability, and motor-intent signals were converted into digital actions throughout the study. The disclosure was not a two-year pivotal-trial report.